Ex vivo methods for drug discovery, development and testing
First Claim
Patent Images
1. A method of developing a pharmaceutical product, comprising:
- passing a perfusate comprising at least one substance to be evaluated through at least one metabolically active human organ selected from the group consisting of liver, lung, kidney, heart, pancreas, testes, thymus, adrenal gland, and lymph nodes that has been permanently removed from its origin and is unsuitable for transplantation, wherein the perfusate is delivered via a perfusion apparatus;
collecting data derived from the perfused organ and storing the data in a computer-readable medium, wherein the data is evaluated via a computer analysis to identify similarities or patterns;
including at least one of the following;
substance absorption by the organ, substance bioavailability, substance toxicity, substance interaction with at least one other substance, substance therapeutic effect, substance metabolite generation or liver clearance of the substance;
quantifying a functional state of the at least one metabolically active human organ selected from the group consisting of liver, lung, kidney, heart, pancreas, testes, thymus, adrenal gland, and lymph nodes by including positive and negative controls in a perfusate that does not contain the at least one substance to be evaluated that is passed through the least one metabolically active human organ after perfusing the at least one metabolically active human organ with the perfusate that contains the at least one substance to be evaluated, wherein the at least one metabolically active human organ selected from the group consisting of liver, lung, kidney, heart, pancreas, testes, thymus, adrenal gland, and lymph nodes acts as its own control; and
continuing or terminating development of the substance into a pharmaceutical product based upon an analysis of the collected data.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for assaying properties in tissues or organs of drugs and other chemical compounds and substances include ex vivo normothermic perfusion with a fluid containing a test substance to obtain data regarding the tissue or organ, the substance and/or an interaction of the substance and the tissue or organ. The data can be used as, for example, part of a submission to a government regulatory organization.
33 Citations
28 Claims
-
1. A method of developing a pharmaceutical product, comprising:
-
passing a perfusate comprising at least one substance to be evaluated through at least one metabolically active human organ selected from the group consisting of liver, lung, kidney, heart, pancreas, testes, thymus, adrenal gland, and lymph nodes that has been permanently removed from its origin and is unsuitable for transplantation, wherein the perfusate is delivered via a perfusion apparatus; collecting data derived from the perfused organ and storing the data in a computer-readable medium, wherein the data is evaluated via a computer analysis to identify similarities or patterns;
including at least one of the following;
substance absorption by the organ, substance bioavailability, substance toxicity, substance interaction with at least one other substance, substance therapeutic effect, substance metabolite generation or liver clearance of the substance;quantifying a functional state of the at least one metabolically active human organ selected from the group consisting of liver, lung, kidney, heart, pancreas, testes, thymus, adrenal gland, and lymph nodes by including positive and negative controls in a perfusate that does not contain the at least one substance to be evaluated that is passed through the least one metabolically active human organ after perfusing the at least one metabolically active human organ with the perfusate that contains the at least one substance to be evaluated, wherein the at least one metabolically active human organ selected from the group consisting of liver, lung, kidney, heart, pancreas, testes, thymus, adrenal gland, and lymph nodes acts as its own control; and continuing or terminating development of the substance into a pharmaceutical product based upon an analysis of the collected data. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
-
15. The method of 14, wherein
the organ is a liver, the at least one substance and the positive and negative controls are delivered via matched blood-based perfusate at physiological flow rates to the liver, and the step of collecting data derived from the perfused organ comprises: -
determining the nature and extent of uptake, metabolism and clearance of the at least one substance, assessing biliary elimination and mass-balance of the at least one substance, and preforming measurements of the subsequent partitioning of metabolites between blood and bile.
-
Specification